Clinical significance of lymphoid enhancer-binding factor 1 expression in acute myeloid leukemia
暂无分享,去创建一个
Wei Wu | Huayuan Zhu | Peng Liu | Wei Wu | P. Liu | Jiadai Xu | Jianyong Li | Jianyong Li | Yuan Fu | Jiadai Xu | Tingmei Chen | Bei Xu | Sixuan Qian | S. Qian | Bei Xu | tingmei chen | Huayuan Zhu | Yuan Fu | Peng Liu
[1] Louise R Howe,et al. Wnt Signaling and Breast Cancer , 2004, Cancer biology & therapy.
[2] Donna Neuberg,et al. Inactivation of LEF1 in T-cell acute lymphoblastic leukemia. , 2010, Blood.
[3] A. Schambach,et al. LEF-1 is crucial for neutrophil granulocytopoiesis and its expression is severely reduced in congenital neutropenia , 2006, Nature Medicine.
[4] Ping Ji,et al. Translocation Products in Acute Myeloid Leukemia Activate the Wnt Signaling Pathway in Hematopoietic Cells , 2004, Molecular and Cellular Biology.
[5] Stefan Fröhling,et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. , 2005, Blood.
[6] Jian Li,et al. Dysregulation of TNFα-induced necroptotic signaling in chronic lymphocytic leukemia: suppression of CYLD gene by LEF1 , 2010, Leukemia.
[7] E. Thiel,et al. Overexpression of LEF1 predicts unfavorable outcome in adult patients with B-precursor acute lymphoblastic leukemia. , 2011, Blood.
[8] Lars Bullinger,et al. High expression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemia. , 2012, Blood.
[9] C. A. Juttner,et al. The Acute Leukemias , 1988 .
[10] R. Grosschedl,et al. Wnt signaling in lymphopoiesis. , 2005, Current topics in microbiology and immunology.
[11] A. Harris,et al. Differential expression of human Wnt genes 2, 3, 4, and 7B in human breast cell lines and normal and disease states of human breast tissue. , 1994, Cancer research.
[12] Axel Benner,et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. , 2002, Blood.
[13] H. Clevers,et al. WNT Signaling and Lymphocyte Development , 2002, Cell.
[14] K. Kreuzer,et al. High lymphoid enhancer-binding factor-1 expression is associated with disease progression and poor prognosis in chronic lymphocytic leukemia , 2010, Hematology reports.
[15] S. Barolo,et al. Transgenic Wnt/TCF pathway reporters: all you need is Lef? , 2006, Oncogene.
[16] B. Smith,et al. Prognostically important molecular markers in cytogenetically normal acute myeloid leukemia. , 2011, The American journal of the medical sciences.
[17] M. Minden,et al. Influence of FLT3‐internal tandem duplication allele burden and white blood cell count on the outcome in patients with intermediate‐risk karyotype acute myeloid leukemia , 2012, Cancer.
[18] H. Clevers,et al. Wnt signalling in stem cells and cancer , 2005, Nature.
[19] K. Uematsu,et al. Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells , 2004, Oncogene.
[20] A. Zelenetz,et al. Acute lymphoblastic leukemia. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.
[21] Zhi-xiang Shen,et al. The investigation of mutation and single nucleotide polymorphism of receptor tyrosine kinases and downstream scaffold molecules in acute myeloid leukemia , 2006, Leukemia & lymphoma.
[22] M. Waterman,et al. Diversity of LEF/TCF action in development and disease , 2006, Oncogene.
[23] B. Löwenberg,et al. Therapeutic advances in acute myeloid leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] C. Bloomfield,et al. BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] J. Cayuela,et al. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). , 2002, Blood.
[26] R Grosschedl,et al. Wnt signaling regulates B lymphocyte proliferation through a LEF-1 dependent mechanism. , 2000, Immunity.
[27] H. Kantarjian,et al. Acute myeloid leukemia , 2018, Methods in Molecular Biology.
[28] M. Fey,et al. Risk Assessment in Patients with Acute Myeloid Leukemia and a Normal Karyotype , 2005, Clinical Cancer Research.
[29] Albert Gutierrez,et al. LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis. , 2010, Blood.
[30] D. Carrasco,et al. Targeting the β-catenin/TCF transcriptional complex in the treatment of multiple myeloma , 2007, Proceedings of the National Academy of Sciences.
[31] A. Quintás-Cardama. Cytogenetically normal acute myeloid leukemia. , 2008, The New England journal of medicine.
[32] F. Appelbaum. 189 – The Acute Leukemias , 2012 .
[33] Jian-yong Li,et al. Heterogeneous leukemic clones identified by NPM1 mutation analysis in patient with acute monocytic leukemia , 2012, Leukemia & lymphoma.
[34] Christian Buske,et al. A novel role for Lef-1, a central transcription mediator of Wnt signaling, in leukemogenesis , 2008, The Journal of experimental medicine.
[35] K. Uematsu,et al. An Anti-Wnt-2 Monoclonal Antibody Induces Apoptosis in Malignant Melanoma Cells and Inhibits Tumor Growth , 2004, Cancer Research.